[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fmZUG3kvA8oPxA3mlkMlBMxuMIDn272lV18DjH_TBJww":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":65,"rows":72},"Menzies School of Health Research",[4],45,false,7,12,20282,10,[13,15,18,21,24,26,29,31],{"name":14,"count":9},"Malaria",{"name":16,"count":17},"Vivax Malaria",9,{"name":19,"count":20},"Otitis Media",4,{"name":22,"count":23},"Falciparum Malaria",3,{"name":25,"count":23},"Malaria, Vivax",{"name":27,"count":28},"G6PD Deficiency",2,{"name":30,"count":28},"Malaria, Falciparum",{"name":32,"count":33},"Schizophrenia",1,[35,40,45,50,55,60],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05426434","Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment in Pregnancy","2025-03-31","Dihydroartemisinin-Piperaquine",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT06148792","A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria","2027-03-01","Tafenoquine",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT07468526","An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria","2027-12-01","High dose ultra short Primaquine",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07060794","Tafenoquine and ACTs (TADORE- Plus)","2028-06","Tafenoquine plus DHA-Piperaquine",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT07468513","Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.","2028-06-30","Patients with G6PD enzyme activities between 30 and \u003C70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg\u002Fkg\u002Fday for 7 days",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT07578298","THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness","2030-07-31","Nirsevimab",[66,67,68,69,70,71],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[73,98,121,139,160,178,211,232,257,345,373,401,442,464,490,508,533,551,577,595,621,647,673,691,709,727,751,769,787,816,840,866,893,911,936,954,979,1004,1034,1058,1083,1107,1131],{"intervention":64,"totalTrials":33,"cells":74},{"EARLY_PHASE1":75,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":96},{"trials":76,"activeCount":77},[],0,{"trials":79,"activeCount":77},[],{"trials":81,"activeCount":77},[],{"trials":83,"activeCount":77},[],{"trials":85,"activeCount":33,"soonestReadout":63},[86],{"nctId":61,"briefTitle":62,"status":87,"phases":88,"primaryCompletion":63,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":95},"NOT_YET_RECRUITING",[70],"2030-12-31","2026-05-15",1000,[93,94],"Respiratory Syncytial Virus (RSV)","Respiratory Infection Virus",[64],{"trials":97,"activeCount":77},[],{"intervention":59,"totalTrials":33,"cells":99},{"EARLY_PHASE1":100,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":119},{"trials":101,"activeCount":77},[],{"trials":103,"activeCount":77},[],{"trials":105,"activeCount":77},[],{"trials":107,"activeCount":77},[],{"trials":109,"activeCount":33,"soonestReadout":58},[110],{"nctId":56,"briefTitle":57,"status":111,"phases":112,"primaryCompletion":58,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":117},"RECRUITING",[70],"2028-12-31","2024-05-17",100,[16,27],[59,118],"Patients with G6PD enzyme activities \u003C30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg\u002Fkg dose).",{"trials":120,"activeCount":77},[],{"intervention":118,"totalTrials":33,"cells":122},{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":129,"PHASE4":131,"NA":137},{"trials":124,"activeCount":77},[],{"trials":126,"activeCount":77},[],{"trials":128,"activeCount":77},[],{"trials":130,"activeCount":77},[],{"trials":132,"activeCount":33,"soonestReadout":58},[133],{"nctId":56,"briefTitle":57,"status":111,"phases":134,"primaryCompletion":58,"completion":113,"start":114,"enrollment":115,"conditions":135,"interventions":136},[70],[16,27],[59,118],{"trials":138,"activeCount":77},[],{"intervention":54,"totalTrials":33,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":149,"NA":158},{"trials":142,"activeCount":77},[],{"trials":144,"activeCount":77},[],{"trials":146,"activeCount":77},[],{"trials":148,"activeCount":77},[],{"trials":150,"activeCount":33,"soonestReadout":53},[151],{"nctId":51,"briefTitle":52,"status":87,"phases":152,"primaryCompletion":53,"completion":53,"start":153,"enrollment":154,"conditions":155,"interventions":156},[70],"2026-06",507,[16],[54,157],"Tafenoquine plus Artesunate-pyronaridine",{"trials":159,"activeCount":77},[],{"intervention":157,"totalTrials":33,"cells":161},{"EARLY_PHASE1":162,"PHASE1":164,"PHASE2":166,"PHASE3":168,"PHASE4":170,"NA":176},{"trials":163,"activeCount":77},[],{"trials":165,"activeCount":77},[],{"trials":167,"activeCount":77},[],{"trials":169,"activeCount":77},[],{"trials":171,"activeCount":33,"soonestReadout":53},[172],{"nctId":51,"briefTitle":52,"status":87,"phases":173,"primaryCompletion":53,"completion":53,"start":153,"enrollment":154,"conditions":174,"interventions":175},[70],[16],[54,157],{"trials":177,"activeCount":77},[],{"intervention":44,"totalTrials":28,"cells":179},{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":186,"PHASE4":207,"NA":209},{"trials":181,"activeCount":77},[],{"trials":183,"activeCount":77},[],{"trials":185,"activeCount":77},[],{"trials":187,"activeCount":33,"soonestReadout":43},[188,201],{"nctId":189,"briefTitle":190,"status":191,"phases":192,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":196,"interventions":199},"NCT04411836","Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine","COMPLETED",[69],"2024-09-30","2021-04-25",960,[16,197,25,198],"Plasmodium Vivax","Malaria Relapse",[44,200],"Primaquine",{"nctId":41,"briefTitle":42,"status":111,"phases":202,"primaryCompletion":43,"completion":43,"start":203,"enrollment":204,"conditions":205,"interventions":206},[69],"2024-05-10",1090,[16],[44,200],{"trials":208,"activeCount":77},[],{"trials":210,"activeCount":77},[],{"intervention":49,"totalTrials":33,"cells":212},{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":228,"NA":230},{"trials":214,"activeCount":77},[],{"trials":216,"activeCount":77},[],{"trials":218,"activeCount":77},[],{"trials":220,"activeCount":33,"soonestReadout":48},[221],{"nctId":46,"briefTitle":47,"status":87,"phases":222,"primaryCompletion":48,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":227},[69],"2028-04-01","2026-06-01",1019,[14],[49],{"trials":229,"activeCount":77},[],{"trials":231,"activeCount":77},[],{"intervention":233,"totalTrials":33,"cells":234},"Sulfadoxine pyrimethamine",{"EARLY_PHASE1":235,"PHASE1":237,"PHASE2":239,"PHASE3":241,"PHASE4":253,"NA":255},{"trials":236,"activeCount":77},[],{"trials":238,"activeCount":77},[],{"trials":240,"activeCount":77},[],{"trials":242,"activeCount":33,"soonestReadout":38},[243],{"nctId":36,"briefTitle":37,"status":244,"phases":245,"primaryCompletion":38,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":252},"ACTIVE_NOT_RECRUITING",[69],"2025-12","2022-08-31",1172,[14,250,251],"Malaria in Pregnancy","Pregnancy Related",[39,233],{"trials":254,"activeCount":77},[],{"trials":256,"activeCount":77},[],{"intervention":200,"totalTrials":258,"cells":259},8,{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":288,"NA":322},{"trials":261,"activeCount":77},[],{"trials":263,"activeCount":77},[],{"trials":265,"activeCount":77},[],{"trials":267,"activeCount":33,"soonestReadout":43},[268,280,284],{"nctId":269,"briefTitle":270,"status":191,"phases":271,"primaryCompletion":272,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":277},"NCT01708876","P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine",[69],"2014-12","2012-10",250,[276],"Uncomplicated Plasmodium Knowlesi Malaria",[278,279,200],"Artesunate-mefloquine","Chloroquine",{"nctId":189,"briefTitle":190,"status":191,"phases":281,"primaryCompletion":193,"completion":193,"start":194,"enrollment":195,"conditions":282,"interventions":283},[69],[16,197,25,198],[44,200],{"nctId":41,"briefTitle":42,"status":111,"phases":285,"primaryCompletion":43,"completion":43,"start":203,"enrollment":204,"conditions":286,"interventions":287},[69],[16],[44,200],{"trials":289,"activeCount":77},[290,301,312],{"nctId":291,"briefTitle":292,"status":191,"phases":293,"primaryCompletion":294,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":298},"NCT02389374","A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh",[70],"2015-03","2014-08",181,[14],[299,300,200,200],"chloroquine","Artemether-lumefantrine combination",{"nctId":302,"briefTitle":303,"status":191,"phases":304,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":310},"NCT04079621","Short Course Radical Cure of P. Vivax Malaria in Nepal",[70],"2024-03-31","2021-10-27",27,[14,25,309],"Malaria,Falciparum",[311],"primaquine",{"nctId":313,"briefTitle":314,"status":191,"phases":315,"primaryCompletion":316,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":321},"NCT03916003","Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas",[70],"2022-05-14","2022-07-30","2019-08-18",500,[14,16,22],[311],{"trials":323,"activeCount":77},[324,333],{"nctId":325,"briefTitle":326,"status":191,"phases":327,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":332},"NCT01716260","Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan",[],"2015-10","2013-01",24,[16],[279,200],{"nctId":334,"briefTitle":335,"status":336,"phases":337,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":343},"NCT01837992","Safety and Efficacy of Primaquine for P. Vivax","UNKNOWN",[71],"2014-05","2015-05","2013-05",180,[14],[200,344],"delayed primaquine",{"intervention":39,"totalTrials":28,"cells":346},{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":351,"PHASE3":353,"PHASE4":359,"NA":361},{"trials":348,"activeCount":77},[],{"trials":350,"activeCount":77},[],{"trials":352,"activeCount":77},[],{"trials":354,"activeCount":33,"soonestReadout":38},[355],{"nctId":36,"briefTitle":37,"status":244,"phases":356,"primaryCompletion":38,"completion":246,"start":247,"enrollment":248,"conditions":357,"interventions":358},[69],[14,250,251],[39,233],{"trials":360,"activeCount":77},[],{"trials":362,"activeCount":77},[363],{"nctId":364,"briefTitle":365,"status":191,"phases":366,"primaryCompletion":367,"completion":367,"start":294,"enrollment":368,"conditions":369,"interventions":372},"NCT02353494","Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment of Uncomplicated Malaria",[],"2016-05",130,[370,371],"Plasmodium Falciparum Infection","Plasmodium Vivax Infection",[39],{"intervention":300,"totalTrials":28,"cells":374},{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":381,"PHASE4":393,"NA":399},{"trials":376,"activeCount":77},[],{"trials":378,"activeCount":77},[],{"trials":380,"activeCount":77},[],{"trials":382,"activeCount":77},[383],{"nctId":384,"briefTitle":385,"status":191,"phases":386,"primaryCompletion":387,"completion":294,"start":388,"enrollment":389,"conditions":390,"interventions":392},"NCT02001012","P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine",[69],"2015-01","2014-01",123,[391],"Uncomplicated Knowlesi Malaria",[300,279],{"trials":394,"activeCount":77},[395],{"nctId":291,"briefTitle":292,"status":191,"phases":396,"primaryCompletion":294,"completion":294,"start":295,"enrollment":296,"conditions":397,"interventions":398},[70],[14],[299,300,200,200],{"trials":400,"activeCount":77},[],{"intervention":402,"totalTrials":28,"cells":403},"Prevenar13",{"EARLY_PHASE1":404,"PHASE1":406,"PHASE2":408,"PHASE3":410,"PHASE4":412,"NA":440},{"trials":405,"activeCount":77},[],{"trials":407,"activeCount":77},[],{"trials":409,"activeCount":77},[],{"trials":411,"activeCount":77},[],{"trials":413,"activeCount":77},[414,429],{"nctId":415,"briefTitle":416,"status":191,"phases":417,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":422,"interventions":427},"NCT01735084","Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life",[70],"2019-02-14","2019-10-03","2013-03-12",261,[19,423,424,425,426],"Febrile Illness","Cough","Lower Respiratory Tract Infection","Upper Respiratory Tract Infection",[402,428],"Synflorix",{"nctId":430,"briefTitle":431,"status":191,"phases":432,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":438},"NCT01174849","Pneumococcal Vaccines Early and in Combination",[70],"2017-09-21","2018-03-15","2011-08",425,[19],[428,402,439],"COMBO",{"trials":441,"activeCount":77},[],{"intervention":428,"totalTrials":28,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":448,"PHASE3":450,"PHASE4":452,"NA":462},{"trials":445,"activeCount":77},[],{"trials":447,"activeCount":77},[],{"trials":449,"activeCount":77},[],{"trials":451,"activeCount":77},[],{"trials":453,"activeCount":77},[454,458],{"nctId":415,"briefTitle":416,"status":191,"phases":455,"primaryCompletion":418,"completion":419,"start":420,"enrollment":421,"conditions":456,"interventions":457},[70],[19,423,424,425,426],[402,428],{"nctId":430,"briefTitle":431,"status":191,"phases":459,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":460,"interventions":461},[70],[19],[428,402,439],{"trials":463,"activeCount":77},[],{"intervention":465,"totalTrials":33,"cells":466},"PQ supervised",{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":475,"NA":488},{"trials":468,"activeCount":77},[],{"trials":470,"activeCount":77},[],{"trials":472,"activeCount":77},[],{"trials":474,"activeCount":77},[],{"trials":476,"activeCount":77},[477],{"nctId":478,"briefTitle":479,"status":191,"phases":480,"primaryCompletion":481,"completion":481,"start":482,"enrollment":483,"conditions":484,"interventions":486},"NCT02787070","A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)",[70],"2018-11","2016-09-14",420,[485],"Uncomplicated Malaria",[465,487],"PQ unsupervised",{"trials":489,"activeCount":77},[],{"intervention":487,"totalTrials":33,"cells":491},{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":498,"PHASE4":500,"NA":506},{"trials":493,"activeCount":77},[],{"trials":495,"activeCount":77},[],{"trials":497,"activeCount":77},[],{"trials":499,"activeCount":77},[],{"trials":501,"activeCount":77},[502],{"nctId":478,"briefTitle":479,"status":191,"phases":503,"primaryCompletion":481,"completion":481,"start":482,"enrollment":483,"conditions":504,"interventions":505},[70],[485],[465,487],{"trials":507,"activeCount":77},[],{"intervention":509,"totalTrials":33,"cells":510},"Supervised primaquine treatment",{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":519,"NA":531},{"trials":512,"activeCount":77},[],{"trials":514,"activeCount":77},[],{"trials":516,"activeCount":77},[],{"trials":518,"activeCount":77},[],{"trials":520,"activeCount":77},[521],{"nctId":522,"briefTitle":523,"status":524,"phases":525,"primaryCompletion":526,"completion":526,"start":527,"enrollment":77,"conditions":528,"interventions":529},"NCT02793388","A Trial on Supervised Primaquine Use in Ethiopia","WITHDRAWN",[70],"2017-09","2016-09",[14],[509,530],"Unsupervised primaquine treatment",{"trials":532,"activeCount":77},[],{"intervention":530,"totalTrials":33,"cells":534},{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":541,"PHASE4":543,"NA":549},{"trials":536,"activeCount":77},[],{"trials":538,"activeCount":77},[],{"trials":540,"activeCount":77},[],{"trials":542,"activeCount":77},[],{"trials":544,"activeCount":77},[545],{"nctId":522,"briefTitle":523,"status":524,"phases":546,"primaryCompletion":526,"completion":526,"start":527,"enrollment":77,"conditions":547,"interventions":548},[70],[14],[509,530],{"trials":550,"activeCount":77},[],{"intervention":552,"totalTrials":33,"cells":553},"Pioglitazone",{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":575},{"trials":555,"activeCount":77},[],{"trials":557,"activeCount":77},[],{"trials":559,"activeCount":77},[],{"trials":561,"activeCount":77},[],{"trials":563,"activeCount":77},[564],{"nctId":565,"briefTitle":566,"status":524,"phases":567,"primaryCompletion":568,"completion":569,"start":570,"enrollment":77,"conditions":571,"interventions":573},"NCT00437970","Medication in Early Diabetes (MED) Study",[70],"2009-01","2009-02","2008-04",[572],"Diabetes Mellitus, Type 2",[552,574],"Metformin",{"trials":576,"activeCount":77},[],{"intervention":574,"totalTrials":33,"cells":578},{"EARLY_PHASE1":579,"PHASE1":581,"PHASE2":583,"PHASE3":585,"PHASE4":587,"NA":593},{"trials":580,"activeCount":77},[],{"trials":582,"activeCount":77},[],{"trials":584,"activeCount":77},[],{"trials":586,"activeCount":77},[],{"trials":588,"activeCount":77},[589],{"nctId":565,"briefTitle":566,"status":524,"phases":590,"primaryCompletion":568,"completion":569,"start":570,"enrollment":77,"conditions":591,"interventions":592},[70],[572],[552,574],{"trials":594,"activeCount":77},[],{"intervention":596,"totalTrials":33,"cells":597},"Thiamine Hydrochloride",{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":606,"NA":619},{"trials":599,"activeCount":77},[],{"trials":601,"activeCount":77},[],{"trials":603,"activeCount":77},[],{"trials":605,"activeCount":77},[],{"trials":607,"activeCount":77},[608],{"nctId":609,"briefTitle":610,"status":191,"phases":611,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":618},"NCT02788552","Optimum Thiamine Intervention (OpTIn) Trial",[70],"2019-05-30","2019-08-01","2014-09",334,[617],"Wernicke-Korsakoff Syndrome",[596],{"trials":620,"activeCount":77},[],{"intervention":622,"totalTrials":33,"cells":623},"Amoxicillin-clavulanic Acid",{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":632,"NA":645},{"trials":625,"activeCount":77},[],{"trials":627,"activeCount":77},[],{"trials":629,"activeCount":77},[],{"trials":631,"activeCount":77},[],{"trials":633,"activeCount":77},[634],{"nctId":635,"briefTitle":636,"status":191,"phases":637,"primaryCompletion":638,"completion":639,"start":640,"enrollment":641,"conditions":642,"interventions":644},"NCT02783859","Hospitalised Pneumonia With Extended Treatment (HOPE) Study",[70],"2022-06","2022-12","2016-06",314,[643],"Pneumonia",[622],{"trials":646,"activeCount":77},[],{"intervention":648,"totalTrials":33,"cells":649},"ASP",{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":658,"NA":671},{"trials":651,"activeCount":77},[],{"trials":653,"activeCount":77},[],{"trials":655,"activeCount":77},[],{"trials":657,"activeCount":77},[],{"trials":659,"activeCount":77},[660],{"nctId":661,"briefTitle":662,"status":191,"phases":663,"primaryCompletion":367,"completion":367,"start":664,"enrollment":665,"conditions":666,"interventions":667},"NCT02592408","A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan",[70],"2015-11",320,[14],[648,668,669,670],"SDPQ","14DPQ","14DPQ on Day 42",{"trials":672,"activeCount":77},[],{"intervention":668,"totalTrials":33,"cells":674},{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":681,"PHASE4":683,"NA":689},{"trials":676,"activeCount":77},[],{"trials":678,"activeCount":77},[],{"trials":680,"activeCount":77},[],{"trials":682,"activeCount":77},[],{"trials":684,"activeCount":77},[685],{"nctId":661,"briefTitle":662,"status":191,"phases":686,"primaryCompletion":367,"completion":367,"start":664,"enrollment":665,"conditions":687,"interventions":688},[70],[14],[648,668,669,670],{"trials":690,"activeCount":77},[],{"intervention":669,"totalTrials":33,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":701,"NA":707},{"trials":694,"activeCount":77},[],{"trials":696,"activeCount":77},[],{"trials":698,"activeCount":77},[],{"trials":700,"activeCount":77},[],{"trials":702,"activeCount":77},[703],{"nctId":661,"briefTitle":662,"status":191,"phases":704,"primaryCompletion":367,"completion":367,"start":664,"enrollment":665,"conditions":705,"interventions":706},[70],[14],[648,668,669,670],{"trials":708,"activeCount":77},[],{"intervention":670,"totalTrials":33,"cells":710},{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":717,"PHASE4":719,"NA":725},{"trials":712,"activeCount":77},[],{"trials":714,"activeCount":77},[],{"trials":716,"activeCount":77},[],{"trials":718,"activeCount":77},[],{"trials":720,"activeCount":77},[721],{"nctId":661,"briefTitle":662,"status":191,"phases":722,"primaryCompletion":367,"completion":367,"start":664,"enrollment":665,"conditions":723,"interventions":724},[70],[14],[648,668,669,670],{"trials":726,"activeCount":77},[],{"intervention":728,"totalTrials":33,"cells":729},"Amoxycillin",{"EARLY_PHASE1":730,"PHASE1":732,"PHASE2":734,"PHASE3":736,"PHASE4":738,"NA":749},{"trials":731,"activeCount":77},[],{"trials":733,"activeCount":77},[],{"trials":735,"activeCount":77},[],{"trials":737,"activeCount":77},[],{"trials":739,"activeCount":77},[740],{"nctId":741,"briefTitle":742,"status":191,"phases":743,"completion":744,"start":745,"enrollment":746,"conditions":747,"interventions":748},"NCT00539149","Long-term Antibiotics for Treatment and Prevention of Otitis Media in Aborignal Children",[70],"2001-03","1996-04",126,[19],[728],{"trials":750,"activeCount":77},[],{"intervention":439,"totalTrials":33,"cells":752},{"EARLY_PHASE1":753,"PHASE1":755,"PHASE2":757,"PHASE3":759,"PHASE4":761,"NA":767},{"trials":754,"activeCount":77},[],{"trials":756,"activeCount":77},[],{"trials":758,"activeCount":77},[],{"trials":760,"activeCount":77},[],{"trials":762,"activeCount":77},[763],{"nctId":430,"briefTitle":431,"status":191,"phases":764,"primaryCompletion":433,"completion":434,"start":435,"enrollment":436,"conditions":765,"interventions":766},[70],[19],[428,402,439],{"trials":768,"activeCount":77},[],{"intervention":278,"totalTrials":33,"cells":770},{"EARLY_PHASE1":771,"PHASE1":773,"PHASE2":775,"PHASE3":777,"PHASE4":783,"NA":785},{"trials":772,"activeCount":77},[],{"trials":774,"activeCount":77},[],{"trials":776,"activeCount":77},[],{"trials":778,"activeCount":77},[779],{"nctId":269,"briefTitle":270,"status":191,"phases":780,"primaryCompletion":272,"completion":272,"start":273,"enrollment":274,"conditions":781,"interventions":782},[69],[276],[278,279,200],{"trials":784,"activeCount":77},[],{"trials":786,"activeCount":77},[],{"intervention":788,"totalTrials":33,"cells":789},"23vPPV, dTpa",{"EARLY_PHASE1":790,"PHASE1":792,"PHASE2":794,"PHASE3":796,"PHASE4":812,"NA":814},{"trials":791,"activeCount":77},[],{"trials":793,"activeCount":77},[],{"trials":795,"activeCount":77},[],{"trials":797,"activeCount":77},[798],{"nctId":799,"briefTitle":800,"status":191,"phases":801,"primaryCompletion":802,"completion":803,"start":804,"enrollment":805,"conditions":806,"interventions":811},"NCT00714064","PneuMum: Pneumococcal Vaccination of Australian Indigenous Mothers",[69],"2011-02","2011-07","2006-06",227,[807,808,809,810],"Middle Ear Effusion","Tympanic Membrane Perforation","Acute Otitis Media","Pneumococcal Infections",[788,788,788],{"trials":813,"activeCount":77},[],{"trials":815,"activeCount":77},[],{"intervention":817,"totalTrials":33,"cells":818},"Paracetamol",{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":823,"PHASE3":825,"PHASE4":836,"NA":838},{"trials":820,"activeCount":77},[],{"trials":822,"activeCount":77},[],{"trials":824,"activeCount":77},[],{"trials":826,"activeCount":77},[827],{"nctId":828,"briefTitle":829,"status":191,"phases":830,"primaryCompletion":831,"completion":831,"start":832,"enrollment":833,"conditions":834,"interventions":835},"NCT03056391","Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria",[69],"2018-02-01","2016-10",360,[14],[817],{"trials":837,"activeCount":77},[],{"trials":839,"activeCount":77},[],{"intervention":841,"totalTrials":33,"cells":842},"Beta-Lactam",{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":862,"NA":864},{"trials":844,"activeCount":77},[],{"trials":846,"activeCount":77},[],{"trials":848,"activeCount":77},[],{"trials":850,"activeCount":77},[851],{"nctId":852,"briefTitle":853,"status":854,"phases":855,"primaryCompletion":856,"completion":856,"start":857,"enrollment":858,"conditions":859,"interventions":861},"NCT02365493","Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection","TERMINATED",[69],"2018-10-24","2015-08-26",358,[860],"Methicillin-Resistant Staphylococcus Aureus",[841],{"trials":863,"activeCount":77},[],{"trials":865,"activeCount":77},[],{"intervention":867,"totalTrials":33,"cells":868},"L-arginine",{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":889,"NA":891},{"trials":870,"activeCount":77},[],{"trials":872,"activeCount":77},[],{"trials":874,"activeCount":77},[],{"trials":876,"activeCount":77},[877],{"nctId":878,"briefTitle":879,"status":191,"phases":880,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":887},"NCT00677339","L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB)",[69],"2010-02","2010-05","2008-06",200,[886],"Smear Positive Pulmonary Tuberculosis",[867,888],"Vitamin D",{"trials":890,"activeCount":77},[],{"trials":892,"activeCount":77},[],{"intervention":888,"totalTrials":33,"cells":894},{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":901,"PHASE4":907,"NA":909},{"trials":896,"activeCount":77},[],{"trials":898,"activeCount":77},[],{"trials":900,"activeCount":77},[],{"trials":902,"activeCount":77},[903],{"nctId":878,"briefTitle":879,"status":191,"phases":904,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":905,"interventions":906},[69],[886],[867,888],{"trials":908,"activeCount":77},[],{"trials":910,"activeCount":77},[],{"intervention":912,"totalTrials":33,"cells":913},"Artemether-lumefantrine + Primaquine",{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":920,"PHASE4":932,"NA":934},{"trials":915,"activeCount":77},[],{"trials":917,"activeCount":77},[],{"trials":919,"activeCount":77},[],{"trials":921,"activeCount":77},[922],{"nctId":923,"briefTitle":924,"status":336,"phases":925,"primaryCompletion":926,"completion":926,"start":387,"enrollment":927,"conditions":928,"interventions":930},"NCT02348788","Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia",[69],"2017-12",98,[929],"Plasmodium Vivax Malaria Without Complication",[912,931],"Chloroquine + Primaquine",{"trials":933,"activeCount":77},[],{"trials":935,"activeCount":77},[],{"intervention":931,"totalTrials":33,"cells":937},{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":944,"PHASE4":950,"NA":952},{"trials":939,"activeCount":77},[],{"trials":941,"activeCount":77},[],{"trials":943,"activeCount":77},[],{"trials":945,"activeCount":77},[946],{"nctId":923,"briefTitle":924,"status":336,"phases":947,"primaryCompletion":926,"completion":926,"start":387,"enrollment":927,"conditions":948,"interventions":949},[69],[929],[912,931],{"trials":951,"activeCount":77},[],{"trials":953,"activeCount":77},[],{"intervention":955,"totalTrials":33,"cells":956},"L-arginine hydrochloride",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":958,"activeCount":77},[],{"trials":960,"activeCount":77},[],{"trials":962,"activeCount":77},[963],{"nctId":964,"briefTitle":965,"status":966,"phases":967,"primaryCompletion":968,"start":969,"enrollment":258,"conditions":970,"interventions":972},"NCT00616304","Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria","SUSPENDED",[68],"2009-03","2008-02",[971],"Severe Falciparum Malaria",[955],{"trials":974,"activeCount":77},[],{"trials":976,"activeCount":77},[],{"trials":978,"activeCount":77},[],{"intervention":980,"totalTrials":33,"cells":981},"intravenous (IV) arginine",{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":998,"PHASE4":1000,"NA":1002},{"trials":983,"activeCount":77},[],{"trials":985,"activeCount":77},[],{"trials":987,"activeCount":77},[988],{"nctId":989,"briefTitle":990,"status":191,"phases":991,"primaryCompletion":992,"completion":993,"start":994,"enrollment":995,"conditions":996,"interventions":997},"NCT00147368","Arginine Malaria Trial: Study of Adjunctive Arginine in Falciparum Malaria",[67,68],"2006-04","2007-12","2005-02",50,[30],[980],{"trials":999,"activeCount":77},[],{"trials":1001,"activeCount":77},[],{"trials":1003,"activeCount":77},[],{"intervention":279,"totalTrials":20,"cells":1005},{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1012,"PHASE4":1022,"NA":1028},{"trials":1007,"activeCount":77},[],{"trials":1009,"activeCount":77},[],{"trials":1011,"activeCount":77},[],{"trials":1013,"activeCount":77},[1014,1018],{"nctId":269,"briefTitle":270,"status":191,"phases":1015,"primaryCompletion":272,"completion":272,"start":273,"enrollment":274,"conditions":1016,"interventions":1017},[69],[276],[278,279,200],{"nctId":384,"briefTitle":385,"status":191,"phases":1019,"primaryCompletion":387,"completion":294,"start":388,"enrollment":389,"conditions":1020,"interventions":1021},[69],[391],[300,279],{"trials":1023,"activeCount":77},[1024],{"nctId":291,"briefTitle":292,"status":191,"phases":1025,"primaryCompletion":294,"completion":294,"start":295,"enrollment":296,"conditions":1026,"interventions":1027},[70],[14],[299,300,200,200],{"trials":1029,"activeCount":77},[1030],{"nctId":325,"briefTitle":326,"status":191,"phases":1031,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":1032,"interventions":1033},[],[16],[279,200],{"intervention":1035,"totalTrials":33,"cells":1036},"Chloroquine and sulphadoxine-pyrimethamine",{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1043,"PHASE4":1045,"NA":1047},{"trials":1038,"activeCount":77},[],{"trials":1040,"activeCount":77},[],{"trials":1042,"activeCount":77},[],{"trials":1044,"activeCount":77},[],{"trials":1046,"activeCount":77},[],{"trials":1048,"activeCount":77},[1049],{"nctId":1050,"briefTitle":1051,"status":191,"phases":1052,"completion":1053,"start":1054,"enrollment":1055,"conditions":1056,"interventions":1057},"NCT00157859","To Evaluate Current Efficacy of Antimalarials Used in Timika, Papua, Indonesia",[71],"2004-09","2004-04",150,[22,16],[1035],{"intervention":1059,"totalTrials":33,"cells":1060},"Revised case management package",{"EARLY_PHASE1":1061,"PHASE1":1063,"PHASE2":1065,"PHASE3":1067,"PHASE4":1069,"NA":1071},{"trials":1062,"activeCount":77},[],{"trials":1064,"activeCount":77},[],{"trials":1066,"activeCount":77},[],{"trials":1068,"activeCount":77},[],{"trials":1070,"activeCount":77},[],{"trials":1072,"activeCount":77},[1073],{"nctId":1074,"briefTitle":1075,"status":191,"phases":1076,"primaryCompletion":1077,"completion":1078,"start":1079,"enrollment":1080,"conditions":1081,"interventions":1082},"NCT05879224","Short Course Primaquine for the Radical Cure of P. Vivax Malaria - Indonesia",[71],"2025-11-01","2025-12-17","2023-08-07",2999,[16,27],[1059],{"intervention":1084,"totalTrials":33,"cells":1085},"Amodiaquine plus artesunate; Artekin",{"EARLY_PHASE1":1086,"PHASE1":1088,"PHASE2":1090,"PHASE3":1092,"PHASE4":1094,"NA":1096},{"trials":1087,"activeCount":77},[],{"trials":1089,"activeCount":77},[],{"trials":1091,"activeCount":77},[],{"trials":1093,"activeCount":77},[],{"trials":1095,"activeCount":77},[],{"trials":1097,"activeCount":77},[1098],{"nctId":1099,"briefTitle":1100,"status":191,"phases":1101,"completion":1102,"start":1103,"enrollment":1104,"conditions":1105,"interventions":1106},"NCT00157885","A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia.",[71],"2005-12","2005-07",400,[30,25],[1084],{"intervention":1108,"totalTrials":33,"cells":1109},"Artekin \u002F Coartemther",{"EARLY_PHASE1":1110,"PHASE1":1112,"PHASE2":1114,"PHASE3":1116,"PHASE4":1118,"NA":1120},{"trials":1111,"activeCount":77},[],{"trials":1113,"activeCount":77},[],{"trials":1115,"activeCount":77},[],{"trials":1117,"activeCount":77},[],{"trials":1119,"activeCount":77},[],{"trials":1121,"activeCount":77},[1122],{"nctId":1123,"briefTitle":1124,"status":191,"phases":1125,"completion":1126,"start":1127,"enrollment":1128,"conditions":1129,"interventions":1130},"NCT00157833","A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.",[71],"2005-08","2004-07",750,[22,16],[1108],{"intervention":344,"totalTrials":33,"cells":1132},{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1137,"PHASE3":1139,"PHASE4":1141,"NA":1143},{"trials":1134,"activeCount":77},[],{"trials":1136,"activeCount":77},[],{"trials":1138,"activeCount":77},[],{"trials":1140,"activeCount":77},[],{"trials":1142,"activeCount":77},[],{"trials":1144,"activeCount":77},[1145],{"nctId":334,"briefTitle":335,"status":336,"phases":1146,"primaryCompletion":338,"completion":339,"start":340,"enrollment":341,"conditions":1147,"interventions":1148},[71],[14],[200,344]]